Drug regulator signals innovation-friendly regulatory approach
Subscribe to keep reading.
Sign up to stay briefed on what the Chinese government is doing, thinking, and saying.
Already a subscriber? Log in.
China wants to move from follower to frontrunner in pharmaceutical innovation.
Li Li – head of China’s drug regulator (NMPA) – said as much during a December 11 interview, in which he outlined regulatory priorities through 2030.
ICYDK: China’s pharmaceutical industry has changed dramatically in re...